Ballantyne et al 1 compared the coronary heart disease (CHD) event rate and the response to simvastatin therapy in a subgroup of approximately 500 individuals from the Scandinavian Simvastatin Survival Study (4S) study with "isolated increased LDL-C" with a similarly-sized subgroup that had not only an increased LDL cholesterol (LDL-C), but also the lowest levels of HDL cholesterol (HDL-C) and highest levels of triglycerides ("the lipid triad") in 4S. The group with the lipid triad was found to have a higher CHD event rate and a greater reduction in CHD events with simvastatin therapy than those with an isolated increased LDL-C.
Response
In response to Dr Robins, we agree that the observations of markedly increased risk for coronary heart disease (CHD) events and response to simvastatin observed in the Scandinavian Simvastatin Survival Study (4S) 1 may not be applicable to groups with average or low levels of LDL cholesterol (LDL-C). The levels of HDL cholesterol (HDL-C) observed in the highest quartile (Ͼ1.32 mmol/L [52 mg/dL]) are higher than are commonly seen in men with CHD; that is why women made up ‫%43ف‬ of this group. In the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) Prevenzione study, 2 28% of the women had an HDL-C level Ͼ1.42 mmol/L (55 mg/dL). It is not clear that the results from GISSIPrevenzione can be used to support the argument that the influence of HDL-C would be any different for men with average versus high HDL-C. Indeed, there was no significant difference in GISSI in relative risk for death among men with HDL-C of 1.06 to 1.42 mmol/L (41 to 55 mg/dL) versus Ͼ1.42 mmol/L (55 mg/dL) in the fully adjusted model, and therefore no difference in the risk points for men with HDL-C in either of these strata. We believe that the most important clinical issue is not whether there is a differential response to statins in patients with low versus high levels of HDL-C, but "whether optimal therapy for these high-risk individuals should consist of high-dose statin monotherapy, fibrate monotherapy, or combination therapy with statin plus fibrate" 1 or other agents to raise HDL-C.
